Cancer Treatment Selection
Actionable, Personalized, EXpress (APEX)
APEX Tissue for Personalized Cancer Treatment Selection
APEX Tissue is a 50-gene, targeted Next-Generation Sequencing (NGS) hotspot panel, which is specially curated for the detection of sensitizing and resistance genetic alterations to guide personalized treatment selection in patients with solid tumours.
Short turnaround time of
4 working days* to allow quicker treatment initiation
Competitively priced for greater affordability and accessibility
Targeted hotspot sequencing of 50 genes specially curated based on clinical actionability
DNA & RNA
Profiling both DNA and RNA for reliable detection of genetic alterations
APEX Tissue has been clinically validated
Profiling various types of genetic alterations, such as SNVs, InDels, amplifications, and fusions, in a single test
Including treatment recommendations based on FDA approvals, NCCN and ESMO guidelines
Easy-to-read report with tier classification of variants for quick decision making
*Counting from the day the specimen is received at our laboratory in Singapore. SNVs: single nucleotide variants; InDels: insertions and deletions.
Gene List (50 genes)
Patient Profiles Suitable for APEX Tissue
Newly diagnosed, treatment-naïve patients with advanced NSCLC for 1L treatment selection.
Relapsed patients who progressed on 1L/2L EGFR, ALK or ROS1 TKI.
Newly diagnosed, treatment-naïve patients with metastic CRC, in which testing for KRAS/NRAS/BRAF status is intended.
HR+/HER2- BC patients who progressed on CDK4/6 inhibitor + AI, in which testing for resistance mutations is intended.
Note: Not suitable for patients who have failed multiple treatments and exhausted most treatment options. A larger panel may be warranted in these patients
Guidelines Recommended Genetic Biomarkers Testing for Solid Tumours
Updated as of 29 March 2022
(5-10 µm thick) on uncoated/uncharged slides
Provide 1 matching H&E stained with tumour region marked out
Tumour cellularity: ≥ 30% Tumour region: ≥ 5mm2
Place all the slides in the slide holders provided
Ordering Process for Physicians
Request a kit online or contact our local representative
Obtain informed consent from patient
Request tissue slides and histopathology report from pathology laboratory
Place all forms and slides in the box provided
Contact our local representative to arrange for pickup and courier to Singapore laboratory
1National Comprehensive Cancer Network. Non–Small Cell Lung Cancer (Version 3.2022). https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Accessed on 18 March 2022.
2National Comprehensive Cancer Network. Breast Cancer (Version 2.2022). https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed on 18 March 2022.
3National Comprehensive Cancer Network. Colon Cancer (Version 1.2022). https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf. Accessed on 18 March 2022.
4National Comprehensive Cancer Network. Rectal Cancer (Version 1.2022). https://www.nccn.org/professionals/physician_gls/pdf/rectal.pdf. Accessed on 18 March 2022.
5National Comprehensive Cancer Network. Melanoma: Cutaneous (Version 2.2022). https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf. Accessed on 18 March 2022.
6National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) (Version 1.2022). https://www.nccn.org/professionals/physician_gls/pdf/gist.pdf. Accessed on 18 March 2022.
7National Comprehensive Cancer Network. Bladder Cancer (Version 1.2022). https://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf. Accessed on 18 March 2022.
8National Comprehensive Cancer Network. Thyroid Carcinoma (Version 3.2021). https://www.nccn.org/professionals/physician_gls/pdf/thyroid.pdf. Accessed on 18 March 2022.
9National Comprehensive Cancer Network. Hepatobiliary Cancers (Version 5.2021). https://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf. Accessed on 8 March 2022
10Mosele F et al. Recommendations for the Use of Next-Generation Sequencing (NGS) for Patients with Metastatic Cancers: A Report from the ESMO Precision Medicine Working Group. Ann Oncol. 2020 Nov;31(11):1491-1505